List view / Grid view
AstraZeneca has entered into a new global development and commercialisation…
AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen.
AZD7442 is the first long acting antibody (LAAB) combination shown…
AZD7442 is the first long acting antibody (LAAB) combination shown to prevent and treat severe COVID-19 infection in Phase III trial.
Avillion reported positive results from MANDALA and DENALI Phase III…
Avillion reported positive results from MANDALA and DENALI Phase III trials of PT027, an albuterol/budesonide combination, in asthma patients.
AstraZeneca’s AZD7442 reduced the risk of developing symptomatic COVID-19 by…
AstraZeneca’s AZD7442 reduced the risk of developing symptomatic COVID-19 by 77 percent in PROVENT Phase III study.
Forxiga’s approval, based on unprecedented Phase III data, is the…
Forxiga’s approval, based on unprecedented Phase III data, is the most significant advancement in chronic kidney disease (CKD) treatment in over 20 years.
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for…
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for patients with moderate to severe systemic lupus erythematosus.
With the addition of the new dermatology trials, Fasenra is…
With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction.
Following DSMB concerns about the data released regarding the Phase…
Following DSMB concerns about the data released regarding the Phase III US trial, AstraZeneca has now confirmed that its vaccine is 76 percent effective against symptomatic COVID-19.
The trial will evaluate if the long-acting monoclonal antibody cocktail,…
The trial will evaluate if the long-acting monoclonal antibody cocktail, AZD7442, can prevent COVID-19 in patients who cannot be vaccinated.
On recommendations by an independent committee, AstraZeneca will close its…
On recommendations by an independent committee, AstraZeneca will close its STRENGTH trial for Epanova, which has shown low likelihood of being beneficial to patients with mixed dyslipidaemia.
As part of EPR’s Women in Pharma series, Ruth March,…
As part of EPR’s Women in Pharma series, Ruth March, VP and Head of Precision Medicine and Genomics at AstraZeneca, talks to Science Editor Dr Zara Kassam about decreasing the clinical risk associated with solid tumour biopsy, balancing a scientific career with family life and taking advantage of company initiatives…
